Atrasentan
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nephropathy
Conditions
Nephropathy, Diabetes
Trial Timeline
Apr 6, 2015 → Jul 16, 2018
NCT ID
NCT02118714About Atrasentan
Atrasentan is a phase 2 stage product being developed by AbbVie for Nephropathy. The current trial status is completed. This product is registered under clinical trial identifier NCT02118714. Target conditions include Nephropathy, Diabetes.
What happened to similar drugs?
6 of 20 similar drugs in Nephropathy were approved
Approved (6) Terminated (3) Active (11)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02118714 | Phase 2 | Completed |
Competing Products
20 competing products in Nephropathy